000827963 001__ 827963
000827963 005__ 20220930130117.0
000827963 0247_ $$2doi$$a10.2967/jnumed.116.187047
000827963 0247_ $$2ISSN$$a0022-3123
000827963 0247_ $$2ISSN$$a0097-9058
000827963 0247_ $$2ISSN$$a0161-5505
000827963 0247_ $$2ISSN$$a1535-5667
000827963 0247_ $$2ISSN$$a2159-662X
000827963 0247_ $$2WOS$$aWOS:000400633500008
000827963 037__ $$aFZJ-2017-01991
000827963 041__ $$aEnglish
000827963 082__ $$a610
000827963 1001_ $$0P:(DE-Juel1)156479$$aStegmayr, Carina$$b0
000827963 245__ $$aInfluence of bevacizumab on blood-brain barrier permeability and O-(2- 18 F-fluoroethyl)-L-tyrosine uptake in rat gliomas
000827963 260__ $$aNew York, NY$$bSoc.$$c2017
000827963 3367_ $$2DRIVER$$aarticle
000827963 3367_ $$2DataCite$$aOutput Types/Journal article
000827963 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1495456860_25475
000827963 3367_ $$2BibTeX$$aARTICLE
000827963 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000827963 3367_ $$00$$2EndNote$$aJournal Article
000827963 520__ $$aRestoration of the blood–brain barrier (BBB) after antiangiogenic therapy of gliomas with bevacizumab may result in a decrease in contrast enhancement on MRI despite tumor progression. This so-called pseudoresponse is difficult to differentiate from a true tumor response with conventional MRI. Initial patient studies have indicated that PET using O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) may be helpful for solving this diagnostic problem. This study was performed to investigate the effects of bevacizumab on BBB permeability and 18F-FET uptake in a human xenograft model. Methods: Human U87 glioblastoma cells were implanted into the striatum of immunodeficient RNU rats. 18F-FET PET scans and ex vivo autoradiography were performed in animals receiving a single high dose of bevacizumab (45 mg/kg 2 d before PET; n = 9) or in animals receiving 2 lower doses (10 mg/kg 9 and 2 d before PET; n = 10) to evaluate short-term and long-term effects on the BBB, respectively, and in control animals without bevacizumab treatment (n = 8). Time–activity curves, slope, and tumor-to-brain ratios of 18F-FET uptake (18–61 min after injection) were evaluated using a volume-of-interest analysis. After PET scanning, Evans blue dye (EBD) was injected into animals, and cryosections of the brains were evaluated by autoradiography, by histology, and for EBD fluorescence to assess BBB permeability. Results: Compared with the control, short-term bevacizumab therapy resulted in a trend toward BBB restoration (P = 0.055) and long-term therapy resulted in a significant decrease (P = 0.004) in BBB permeability, as assessed by EBD fluorescence. In contrast, no significant differences in tumor-to-brain ratios or slope of 18F-FET uptake were observed in PET and autoradiography (P > 0.05). Conclusion: 8F-FET uptake in glioblastomas seems to be largely independent of BBB permeability and reflects the viability of tumor tissue during antiangiogenic therapy more reliably than contrast-enhanced MRI
000827963 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000827963 588__ $$aDataset connected to CrossRef
000827963 7001_ $$0P:(DE-Juel1)165631$$aOliveira, Dennis$$b1
000827963 7001_ $$0P:(DE-Juel1)142279$$aNiemietz, Nicole$$b2
000827963 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b3
000827963 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b4
000827963 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b5
000827963 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b6
000827963 7001_ $$0P:(DE-Juel1)131818$$aErmert, Johannes$$b7
000827963 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8$$eCorresponding author
000827963 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.116.187047$$gp. jnumed.116.187047 -$$n5$$p700-705$$tJournal of nuclear medicine$$v58$$x2159-662X$$y2017
000827963 8767_ $$8AS1EF13DF3BB$$92017-01-18$$d2017-01-18$$ePublication charges$$jZahlung erfolgt$$lKK: Barbers$$pJNUMED/2016/187047$$zPROCCC 2304
000827963 909CO $$ooai:juser.fz-juelich.de:827963$$pOpenAPC$$pVDB$$popenCost
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156479$$aForschungszentrum Jülich$$b0$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165631$$aForschungszentrum Jülich$$b1$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b3$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b4$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b5$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b6$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131818$$aForschungszentrum Jülich$$b7$$kFZJ
000827963 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000827963 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000827963 9141_ $$y2017
000827963 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2015
000827963 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000827963 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000827963 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000827963 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000827963 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000827963 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000827963 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000827963 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000827963 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000827963 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000827963 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2015
000827963 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000827963 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000827963 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000827963 980__ $$ajournal
000827963 980__ $$aVDB
000827963 980__ $$aI:(DE-Juel1)INM-3-20090406
000827963 980__ $$aI:(DE-Juel1)INM-4-20090406
000827963 980__ $$aI:(DE-Juel1)INM-5-20090406
000827963 980__ $$aAPC
000827963 980__ $$aUNRESTRICTED